市場調査レポート
商品コード
1125993
VRAYLAR:新薬の考察と市場予測 (2032年)VRAYLAR Emerging Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
VRAYLAR:新薬の考察と市場予測 (2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
VRAYLARはカリプラジンとも呼ばれる経口非定型の抗精神病薬です。本剤は、強力な中枢性ドパミンD3およびD2受容体の部分作動薬であり、D3受容体に優先的に結合します。また、セロトニン5-HT1A受容体に対しては部分作動薬として、セロトニン5-HT2A受容体に対しては拮抗薬として作用します。カリプラジンの薬力学的研究により、ドパミンD3、ドパミンD2およびセロトニン5-HT1A受容体に高い結合親和性を有する部分作動薬として作用することが示されています。カリプラジンは、ドパミンD3受容体とD2受容体に対して、in vitroで最大8倍の親和性を示しました。また、セロトニン5-HT2Bおよび5-HT2A受容体に対しては、それぞれ高・中程度の結合親和性で拮抗薬として作用し、ヒスタミンH1受容体に対しても結合します。セロトニン5-HT2Cおよびα1Aアドレナリン受容体には低い結合親和性を示し、コリン作動性ムスカリン受容体には顕著な親和性を示しません。
当レポートでは、治療抵抗性うつ病の治療薬の一種であるVRAYLARの市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2023~2032年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、今後の市場成長の可能性などを調査・考察しております。
"VRAYLAR, Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VRAYLAR for Treatment Resistant Depression in seven major markets. A detailed picture of the VRAYLAR for Treatment Resistant Depression in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the VRAYLAR for Treatment Resistant Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VRAYLAR market forecast analysis for Treatment Resistant Depression in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Treatment Resistant Depression.
VRAYLAR also known as Cariprazine is an oral, once-daily atypical antipsychotic. It is a potent central dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. It also has partial agonist activity at serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors. Cariprazine demonstrated up to eightfold greater in vitro affinity for dopamine D3 vs. D2 receptors. Cariprazine also acts as an antagonist at serotonin 5-HT2B and 5-HT2A receptors with high and moderate binding affinity, respectively, as well as it binds to the histamine H1 receptors. It shows a lower binding affinity to the serotonin 5-HT2C and α1A-adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors.
It was discovered and co-developed by Gedeon Richter and is licensed to Actavis, now Allergan, in the US and Canada. For more than a decade, both companies have conducted over 20 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine for patients suffering from a broad range of mental health illnesses.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VRAYLAR Analytical Perspective by DelveInsight
This report provides a detailed market assessment of VRAYLAR for Treatment Resistant Depression in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of VRAYLAR for Treatment Resistant Depression covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions